Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + penpulimab + cisplatin
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
disitamab vedotin + penpulimab + cisplatin is a combination therapy regimen being investigated for the treatment of HER2-positive advanced gastric cancer. The regimen consists of disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate (ADC) developed by RemeGen that delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE); penpulimab (AK105), a humanized PD-1 monoclonal antibody developed by Akeso; and cisplatin, a platinum-based chemotherapeutic agent that induces DNA cross-linking. This triple combination aims to leverage the targeted cytotoxicity of the ADC, the immune-potentiating effects of the checkpoint inhibitor, and the broad antineoplastic activity of cisplatin to improve outcomes in patients with HER2-overexpressing gastric or gastroesophageal junction cancers. It is currently being evaluated in Phase 2 clinical trials sponsored by Henan Cancer Hospital.
- Brand names
- AiditongAnniko
- Other names
- RC48 + AK105 + cisplatinDisitamab vedotin + Penpulimab + Cisplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on disitamab vedotin + penpulimab + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + penpulimab + cisplatin.